Loading organizations...
Banexi Ventures is a venture capital firm based in Paris and Lyon, France, that invests in early-stage and growth-stage companies across the technology and healthcare sectors. The firm primarily provides seed and Series A funding to startups operating in information technology, digital platforms, life sciences, and deeptech throughout the European market. Operating today under the name Kreaxi following a 2014 merger, the combined entity manages approximately €160 million in assets under management and has completed more than 550 investments. Historically, the firm maintained a $1.75 million minimum investment threshold for its early-stage allocations while raising over €500 million across its various funds. The firm's extensive portfolio includes notable technology and medical companies such as PrestaShop, Mister Auto, Erytech Pharma, Agicap, and Nanobiotix. Banexi Ventures was originally founded in 1983 before spinning out of BNP Paribas.
Key people at Banexi Ventures.
Key people at Banexi Ventures.
Banexi Ventures is a Paris-based venture capital firm founded in 1983, specializing in early-stage investments in high-growth technology companies, particularly in sectors like internet technologies, electronics, medical technologies, software, telecom, biotech, fintech, e-commerce, and medtech.[1][2][4][5] The firm invests through venture capital funds, targeting startups aged 4-5 years with high scalability potential, often in rounds of $5-10 million alongside co-investors like Sofinnova Partners and Innovacom, and has backed over 40 companies across France, Europe, and North America with a track record of exits peaking in 2017.[1][4][6] Its philosophy emphasizes hands-on support for innovative projects in high-tech areas, contributing to the startup ecosystem by providing operational guidance and strategic backing to firms like Kelkoo, ScreenCell, and Symetis, though activity has been low (under 2 deals per year recently).[1][2][6]
Banexi Ventures was established in 1983 in Paris, France, as a venture capital firm focused on early-stage high-tech investments.[1][2][4] Key team members have included partners like Jacqueline Renard, Sophie Lepinard, Philippe Herbert, Michel Dahan, and Myriam Prieur, with the firm evolving from broad tech investments to concentrating on internet, electronics, and medical technologies while expanding geographically to regions like Switzerland, the US, UK, and Norway.[1][4][5] Peak activity occurred around 2009, with notable deals in companies like In-Fusio (mobile games in 2004) and a shift toward fewer but targeted investments by the 2010s, leading to exits in 2017; the firm is now listed as closed in some records.[1][6]
Banexi Ventures rode early waves of internet, mobile, and medtech innovation from the 1980s-2010s, capitalizing on Europe's tech boom in France and supporting scalable high-tech firms amid rising VC interest in biotech and digital sectors.[2][4][6] Timing aligned with pre-2010 peaks in early-stage funding, enabling exits during 2017's favorable M&A climate for tech; market forces like EU tech growth and cross-border expansion favored its model.[1] It influenced the ecosystem by nurturing exits in e-commerce (Kelkoo), medtech (Symetis), and mobile (In-Fusio), bridging French startups to international markets despite low recent activity.[1][6]
With its closure noted in records and minimal recent deals, Banexi Ventures' influence appears legacy-focused, shaped by enduring trends in medtech and digital tech that propelled its portfolio successes.[6] Future evolution likely centers on alumni networks or fund liquidations driving ongoing ecosystem impact, as high-growth sectors like AI-medtech and fintech—echoing its original thesis—continue expanding; its hands-on model remains a benchmark for European VCs targeting scalable innovation.[4] This positions it as a foundational player whose early bets humanize the path for today's active funds.
